Abstract

Grifols SA will report second-quarter results on July 28, 2026 after market close; this preview summarizes expected revenue, margins, EPS trajectory, and sentiment into the print.

Market Forecast

For the current quarter, forecasts indicate revenue of 1.96 billion euros, up 5.43% year over year, with estimated EBIT of 353.47 million euros, up 12.10% year over year, and estimated EPS of 0.24 euros, up 20.39% year over year. Forecast margin detail beyond EBIT is not available, but the prior quarter’s gross margin of 37.59% and net margin of 4.29% set the baseline heading into the print. The company’s main business remains Biopharmaceuticals, followed by Diagnostics, Bio Supplies, and Others. The area with the clearest near-term growth initiatives is the immunoglobulins and hemostasis portfolio within Biopharmaceuticals, supported by new product launches and label-expansion studies; segment-level year-over-year growth data was not disclosed.

Last Quarter Review

In the previous quarter, Grifols SA delivered 1.70 billion euros in revenue, a 37.59% gross margin, net profit attributable to the parent company of 73.00 million euros, a net profit margin of 4.29%, and adjusted EPS of 0.23 euros; reported net profit decreased 25.70% quarter on quarter, while adjusted EPS rose 130% year over year. A notable highlight was the adjusted profitability improvement versus expectations, as actual EPS of 0.23 euros exceeded an estimate of 0.14 euros. By business line, Biopharmaceuticals contributed 1.50 billion euros, Diagnostics 142.00 million euros, Bio Supplies 19.00 million euros, and Others 43.00 million euros; segment-level year-over-year growth rates were not disclosed.

Current Quarter Outlook (with major analytical insights)

Main Business: Biopharmaceuticals and core plasma protein therapies

Biopharmaceuticals remains the revenue anchor, driven primarily by immunoglobulins and albumin. The current-quarter setup points to a return to year-over-year growth on the top line, with the revenue estimate up 5.43% and EBIT up 12.10% year over year, implying incremental operating leverage if mix and plasma costs hold near recent levels. The trailing quarter’s 37.59% gross margin and 4.29% net margin serve as context; management execution around product mix and cost discipline will be critical to translate the forecast EBIT uplift into bottom-line momentum. Within the quarter, pricing and mix across immunoglobulins are focal, as the portfolio moves through a normalization phase in supply and demand. The company’s operational cadence around plasma collection, fractionation throughput, and yield efficiencies has been central to margin stabilization in recent periods; sustaining those gains helps reconcile the favorable EBIT estimate with limited visibility on gross margin guidance. A stable unit cost trend would support the forecast EPS growth of 20.39% year over year to 0.24 euros and cushion any variability from currency or regional sales mix. Commercially, channel inventory behavior remains an item to monitor. If order timing and geographic mix skew toward higher-value indications for immunoglobulins, it can foster modest upside to the EBIT trajectory. Conversely, if order timing is uneven, the quarterly cadence could still meet the revenue estimate yet be choppier on margin conversion.

Most Promising Business: Immunoglobulins and hemostasis growth vectors

The most visible growth vectors this quarter are immunoglobulins and hemostasis, supported by new product catalysts and label-expansion work. The United States launch of the fibrinogen concentrate Fesilty (for congenital fibrinogen deficiency) adds a targeted but strategically important revenue stream that complements the hemostasis suite. While its near-term contribution is small relative to the 1.50 billion euros Biopharmaceuticals baseline last quarter, early uptake can enhance overall pricing and mix, reinforcing the EBIT estimate’s double-digit year-over-year growth profile. The company also initiated patient dosing in two Phase 3 trials to expand indications for flagship immunoglobulins, which, although not revenue contributors in the near term, can shape clinician confidence and support sustained demand in core categories. Positive clinical progression can underpin more durable volume and potentially improve realized pricing, given the specialized nature of treatments. Against the quarter’s estimates, even incremental contributions from new launches and clinical momentum can help offset any temporary softness in other sublines. From a market mechanics standpoint, investor attention is likely to center on whether volume growth in immunoglobulins is sufficient to overcome any pressure from localized reimbursement dynamics. Clarity around hospital and specialty-pharmacy throughput and any commentary on patient starts can inform demand durability into the second half.

Key Stock Price Drivers This Quarter: Execution on margins, revenue mix, and capital discipline

The first determinant for the share reaction is margin execution versus the prior quarter’s 37.59% gross margin context. With EBIT estimated to rise 12.10% year over year, investors will look for evidence that cost control and mix improvements are translating into healthier conversion from gross to operating income; confirmation would validate the 20.39% year-over-year EPS estimate. Any commentary on plasma collection costs, yield improvements, and manufacturing efficiencies will be closely parsed to gauge sustainability. The second driver is the revenue mix across immunoglobulins, albumin, and hemostasis. A favorable mix skew toward higher-margin indications can help bridge limited visibility in gross margin forecasting, while a less favorable mix could cap EPS upside even if revenue meets the 1.96 billion euros estimate. Product-level updates, including early Fesilty uptake and progress in immunoglobulin label expansions, can influence sentiment and near-term multiple support. The third driver involves capital and cash flow discipline, given the historical sensitivity of investors to balance sheet narratives. While detailed cash flow metrics are not part of the current forecast set, improving adjusted profitability and stable EBIT progression support the case for gradual balance sheet strengthening. Any updates on working capital cadence, inventory turns, or discretionary spending can either reinforce the constructive view embedded in EPS estimates or prompt near-term caution.

Analyst Opinions

The balance of recent coverage and market commentary since January 2026 has leaned cautiously positive, reflecting acknowledgment of improved adjusted profitability alongside a still-mixed revenue trend. Following the previous quarter’s release, the company reported adjusted profit of 95.00 million euros versus 67.00 million euros a year earlier, modestly beating a 94.10 million euros consensus from two surveyed analysts, and shares were cited as trading higher in the immediate aftermath. This reaction, together with incremental news around a U.S. launch in hemostasis and progress in key immunoglobulin trials, underpins a majority-leaning constructive stance into the Q2 print. The majority view emphasizes three supportive points. First, consensus forecasts embed manageable expectations, with revenue growth estimated at 5.43% year over year and EPS at 0.24 euros, up 20.39% year over year, leaving room for execution-led upside if margins hold near recent levels. Second, the prior quarter demonstrated improved adjusted profitability versus expectations, suggesting underlying efficiency gains that could continue supporting EBIT and EPS. Third, product catalysts, including the Fesilty launch and Phase 3 progress for immunoglobulins, offer incremental growth narratives that can help sustain mix quality even if overall market conditions are uneven. In this framework, the constructive camp views current-quarter EBIT growth of 12.10% year over year as attainable, with the potential for incremental upside if product mix skews favorably and operating cost metrics remain controlled. The cautious tone within this majority view stems from awareness of the prior quarter’s year-over-year revenue decline and the need for consistent top-line reacceleration to complement margin work. Integration of these considerations results in a cautiously positive outlook focused on validation of revenue normalization, margin resilience around the previous 37.59% gross margin marker, and confirmation of the 0.24 euros EPS trajectory.